Background:Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex(encoded by PIK3CA)that also promotes the degradation of ...Background:Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex(encoded by PIK3CA)that also promotes the degradation of mutated p110α.Inavolisib plus palbociclib-fulvestrant has shown synergistic activity in preclinical models and promising antitumor activity in early-phase trials.展开更多
1文献来源Baselga J,Im S-A,Iwata H,et al.PIK3CA status in circulating tumor DNA（ct DNA）predicts efficacy of Buparlisib（BUP）plus Fulvestrant（FULV）in postmenopausal women with endocrine-resistant HR＋/HER2–advance...1文献来源Baselga J,Im S-A,Iwata H,et al.PIK3CA status in circulating tumor DNA（ct DNA）predicts efficacy of Buparlisib（BUP）plus Fulvestrant（FULV）in postmenopausal women with endocrine-resistant HR＋/HER2–advanced breast cancer（BC）：First results from the randomized,phaseⅢBELLE-2trial[C].San Antonio Breast Cancer Symposium,2015,abst S6-01.展开更多
文摘Background:Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex(encoded by PIK3CA)that also promotes the degradation of mutated p110α.Inavolisib plus palbociclib-fulvestrant has shown synergistic activity in preclinical models and promising antitumor activity in early-phase trials.
文摘1文献来源Baselga J,Im S-A,Iwata H,et al.PIK3CA status in circulating tumor DNA（ct DNA）predicts efficacy of Buparlisib（BUP）plus Fulvestrant（FULV）in postmenopausal women with endocrine-resistant HR＋/HER2–advanced breast cancer（BC）：First results from the randomized,phaseⅢBELLE-2trial[C].San Antonio Breast Cancer Symposium,2015,abst S6-01.
